These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 34872775)

  • 21. Effectiveness of first-line cetuximab in wild-type RAS metastatic colorectal cancer according to tumour BRAF mutation status from the EREBUS cohort.
    Rouyer M; François E; Sa Cunha A; Monnereau A; Bignon E; Jové J; Lassalle R; Droz-Perroteau C; Moore N; Noize P; Fourrier-Réglat A; Smith D
    Br J Clin Pharmacol; 2021 Mar; 87(3):1120-1128. PubMed ID: 32656857
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Comparative study on prognosis of neoadjuvant chemotherapy followed by hepatic surgery versus upfront surgery in patients with synchronous colorectal liver metastasis].
    Wang LJ; Wang HW; Jin KM; Liu W; Bao Q; Wang K; Xing BC
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):248-255. PubMed ID: 34645169
    [No Abstract]   [Full Text] [Related]  

  • 23. Primary tumour location affects survival after resection of colorectal liver metastases: A two-institutional cohort study with international validation, systematic meta-analysis and a clinical risk score.
    Gasser E; Braunwarth E; Riedmann M; Cardini B; Fadinger N; Presl J; Klieser E; Ellmerer P; Dupré A; Imai K; Malik H; Baba H; Ulmer H; Schneeberger S; Öfner D; Dinnewitzer A; Stättner S; Primavesi F
    PLoS One; 2019; 14(5):e0217411. PubMed ID: 31150437
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Withholding the Introduction of Anti-Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild-Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study).
    Palmieri LJ; Mineur L; Tougeron D; Rousseau B; Granger V; Gornet JM; Smith D; Lievre A; Galais MP; Doat S; Pernot S; Bignon-Bretagne AL; Metges JP; Baba-Hamed N; Michel P; Obled S; Vitellius C; Bouche O; Saban-Roche L; Buecher B; des Guetz G; Locher C; Trouilloud I; Goujon G; Dior M; Manfredi S; Soularue E; Phelip JM; Henriques J; Vernery D; Coriat R
    Oncologist; 2020 Feb; 25(2):e266-e275. PubMed ID: 32043796
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemotherapy With or Without Anti-EGFR Agents in Left- and Right-Sided Metastatic Colorectal Cancer: An Updated Meta-Analysis.
    Wang ZX; Wu HX; He MM; Wang YN; Luo HY; Ding PR; Xie D; Chen G; Li YH; Wang F; Xu RH
    J Natl Compr Canc Netw; 2019 Jul; 17(7):805-811. PubMed ID: 31319395
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study.
    Goey KKH; Elias SG; van Tinteren H; Laclé MM; Willems SM; Offerhaus GJA; de Leng WWJ; Strengman E; Ten Tije AJ; Creemers GM; van der Velden A; de Jongh FE; Erdkamp FLG; Tanis BC; Punt CJA; Koopman M
    Ann Oncol; 2017 Sep; 28(9):2128-2134. PubMed ID: 28911067
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of primary tumour resection on patients with synchronous metastatic colorectal cancer treated with cetuximab-containing regimens.
    Sertesen E; Yekedüz E; Köksoy EB; Ürün Y; Erkek AB; Demirci S; Ünal AE; Utkan G
    ANZ J Surg; 2023 Apr; 93(4):945-950. PubMed ID: 36259228
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer.
    Heinemann V; Rivera F; O'Neil BH; Stintzing S; Koukakis R; Terwey JH; Douillard JY
    Eur J Cancer; 2016 Nov; 67():11-20. PubMed ID: 27592068
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimization of
    Santos C; Azuara D; Garcia-Carbonero R; Alfonso PG; Carrato A; Elez ME; Gomez A; Losa F; Montagut C; Massuti B; Navarro V; Varela M; Lopez-Doriga A; Moreno V; Valladares M; Manzano JL; Vieitez JM; Aranda E; Sanjuan X; Tabernero J; Capella G; Salazar R
    Mol Cancer Ther; 2017 Sep; 16(9):1999-2007. PubMed ID: 28626084
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Primary tumor sidedness is an independent prognostic marker for survival in metastatic colorectal cancer: Results from a large retrospective cohort with mutational analysis.
    Kamran SC; Clark JW; Zheng H; Borger DR; Blaszkowsky LS; Allen JN; Kwak EL; Wo JY; Parikh AR; Nipp RD; Murphy JE; Goyal L; Zhu AX; Iafrate AJ; Corcoran RB; Ryan DP; Hong TS
    Cancer Med; 2018 Jul; 7(7):2934-2942. PubMed ID: 29771009
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The impact of primary tumor localization on survival and treatment outcomes in patients with metastatic colorectal cancer-a multicenter study.
    Sahin S; Karatas F
    J BUON; 2019; 24(2):479-487. PubMed ID: 31127994
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Impact of PI3K/BRAF Mutations in RAS Wild Metastatic Colorectal Cancer: Meta-analysis Results.
    Mohamed A; Twardy B; AbdAllah N; Akhras A; Ismail H; Zordok M; Schrapp K; Attumi T; Tesfaye A; El-Rayes B
    J Gastrointest Cancer; 2019 Jun; 50(2):269-275. PubMed ID: 29388061
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Post-induction Strategies in Metastatic Colorectal Cancer Patients Treated With First-Line Anti-EGFR-Based Treatment: A Systematic Review and Meta-Analysis.
    Parisi A; Ghidini M; Giampieri R; Tomasello G; Luciani A; Ferri C; Berardi R; Petrelli F
    Clin Colorectal Cancer; 2022 Sep; 21(3):e162-e170. PubMed ID: 35184993
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic importance of tumor location and anti-EGFR therapy in patients with K-RAS wild type metastatic colorectal cancer.
    Kucukoner M; Oztekin E; Akdeniz N; Morkuzu S; Yerlikaya H; Urakci Z; Kaplan MA; Isikdogan A
    J BUON; 2019; 24(4):1501-1506. PubMed ID: 31646798
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Primary tumor location and survival among metastatic colorectal cancer patients treated with systemic chemotherapy and biologic therapies: Retrospective analysis.
    Ramadan M; Alfayea T; Alsofyani A; Alyabsi M; Alhusseini N; Algarni AS
    Cancer Treat Res Commun; 2022; 33():100632. PubMed ID: 36088745
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic significance of primary tumor localization in patients with metastatic colorectal cancer: Is it beneficial to select targeted treatment? Real-life experience from Turkey.
    Cakan B; Acikgoz O; Bilici A; Demir T; Basak Oven B; Hamdard J; Olmuscelik O; Olmez OF; Seker M; Yildiz O
    J BUON; 2021; 26(5):1908-1917. PubMed ID: 34761599
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial.
    Hegewisch-Becker S; Nöpel-Dünnebacke S; Hinke A; Graeven U; Reinacher-Schick A; Hertel J; Lerchenmüller CA; Killing B; Depenbusch R; Al-Batran SE; Lange T; Dietrich G; Tannapfel A; Arnold D
    Eur J Cancer; 2018 Sep; 101():105-113. PubMed ID: 30036739
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies.
    Boeckx N; Koukakis R; Op de Beeck K; Rolfo C; Van Camp G; Siena S; Tabernero J; Douillard JY; André T; Peeters M
    Ann Oncol; 2017 Aug; 28(8):1862-1868. PubMed ID: 28449055
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer.
    Loupakis F; Hurwitz HI; Saltz L; Arnold D; Grothey A; Nguyen QL; Osborne S; Talbot J; Srock S; Lenz HJ
    Br J Cancer; 2018 Dec; 119(12):1451-1455. PubMed ID: 30487637
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Factors Affecting the Efficacy of Regorafenib in Metastatic Colorectal Cancer: Is Tumour Sidedness Important?
    Kazaz SN; Ozdover AC; Usta N; Yildirim A; Fidan E; Ozdemir F
    J Coll Physicians Surg Pak; 2023 Jun; 33(6):659-665. PubMed ID: 37300262
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.